实用检验医师杂志
實用檢驗醫師雜誌
실용검험의사잡지
Chinese Journal of Laboratory Pathologist
2014年
2期
98-101
,共4页
肝病%自身免疫性肝病%自身抗体
肝病%自身免疫性肝病%自身抗體
간병%자신면역성간병%자신항체
Liver disease%Autoimmune liver disease%Autoantibody
目的:探讨各种肝病患者中自身抗体检测在自身免疫性肝病(autoimmune liver disease, ALD)包括自身免疫性肝炎(autoimmune hepatitis, AIH)、原发性胆汁性肝硬化(primary biliary cirrhosis, PBC)及原发性硬化性胆管炎(primary sclerosing cholangitis, PSC)中的临床意义。方法选择我院2013年1月-2014年2月消化科、肝胆外科、移植外科等收治的各种肝病患者225例,分为ALD患者组和其他肝病患者组。用间接免疫荧光法检测225份临床血清标本中抗核抗体(antinuclear antibody, ANA)、抗平滑肌抗体(antismooth muscle antibody, SMA)和抗线粒体抗体(anti-mitochondrial antibody, AMA),用欧蒙印迹法检测抗肝肾微粒体抗体(liver kidney microsomal, LKM)、抗肝细胞溶质抗原Ⅰ型抗体(liver cytosol-1, LC-1)、抗可溶性肝抗原抗体/抗肝胰抗体(anti-soluble liver antigen antibody/liver pancreas antigen, SLA/LP)、AMAⅡ型(AMA-M2)并查阅临床资料,对检测结果作出分析。结果 ALD 患者组ANA阳性率为77.78%,SMA阳性率为7.41%,AMA阳性率为55.56%,LKM 阳性率为7.41%,AMA-M2阳性率为48.15%,SLA/LP 阳性率为7.41%,LC-1阳性率为3.70%。其他肝病患者组 ANA 阳性率为26.26%,SMA 阳性率为4.55%,AMA 阳性率为11.11%,LKM 阳性率为0.51%,AMA-M2阳性率为5.05%,SLA/LP阳性率为2.53%,LC-1阳性率为1.52%。ALD患者组自身抗体阳性率与其他肝病患者组相比较,ANA、AMA、LKM、AMA-M2差异均有统计学意义(P均<0.05)。结论 ALD患者自身抗体检出率较高,为临床医生鉴别病毒性肝炎、ALD及其他肝病提供可靠依据。
目的:探討各種肝病患者中自身抗體檢測在自身免疫性肝病(autoimmune liver disease, ALD)包括自身免疫性肝炎(autoimmune hepatitis, AIH)、原髮性膽汁性肝硬化(primary biliary cirrhosis, PBC)及原髮性硬化性膽管炎(primary sclerosing cholangitis, PSC)中的臨床意義。方法選擇我院2013年1月-2014年2月消化科、肝膽外科、移植外科等收治的各種肝病患者225例,分為ALD患者組和其他肝病患者組。用間接免疫熒光法檢測225份臨床血清標本中抗覈抗體(antinuclear antibody, ANA)、抗平滑肌抗體(antismooth muscle antibody, SMA)和抗線粒體抗體(anti-mitochondrial antibody, AMA),用歐矇印跡法檢測抗肝腎微粒體抗體(liver kidney microsomal, LKM)、抗肝細胞溶質抗原Ⅰ型抗體(liver cytosol-1, LC-1)、抗可溶性肝抗原抗體/抗肝胰抗體(anti-soluble liver antigen antibody/liver pancreas antigen, SLA/LP)、AMAⅡ型(AMA-M2)併查閱臨床資料,對檢測結果作齣分析。結果 ALD 患者組ANA暘性率為77.78%,SMA暘性率為7.41%,AMA暘性率為55.56%,LKM 暘性率為7.41%,AMA-M2暘性率為48.15%,SLA/LP 暘性率為7.41%,LC-1暘性率為3.70%。其他肝病患者組 ANA 暘性率為26.26%,SMA 暘性率為4.55%,AMA 暘性率為11.11%,LKM 暘性率為0.51%,AMA-M2暘性率為5.05%,SLA/LP暘性率為2.53%,LC-1暘性率為1.52%。ALD患者組自身抗體暘性率與其他肝病患者組相比較,ANA、AMA、LKM、AMA-M2差異均有統計學意義(P均<0.05)。結論 ALD患者自身抗體檢齣率較高,為臨床醫生鑒彆病毒性肝炎、ALD及其他肝病提供可靠依據。
목적:탐토각충간병환자중자신항체검측재자신면역성간병(autoimmune liver disease, ALD)포괄자신면역성간염(autoimmune hepatitis, AIH)、원발성담즙성간경화(primary biliary cirrhosis, PBC)급원발성경화성담관염(primary sclerosing cholangitis, PSC)중적림상의의。방법선택아원2013년1월-2014년2월소화과、간담외과、이식외과등수치적각충간병환자225례,분위ALD환자조화기타간병환자조。용간접면역형광법검측225빈림상혈청표본중항핵항체(antinuclear antibody, ANA)、항평활기항체(antismooth muscle antibody, SMA)화항선립체항체(anti-mitochondrial antibody, AMA),용구몽인적법검측항간신미립체항체(liver kidney microsomal, LKM)、항간세포용질항원Ⅰ형항체(liver cytosol-1, LC-1)、항가용성간항원항체/항간이항체(anti-soluble liver antigen antibody/liver pancreas antigen, SLA/LP)、AMAⅡ형(AMA-M2)병사열림상자료,대검측결과작출분석。결과 ALD 환자조ANA양성솔위77.78%,SMA양성솔위7.41%,AMA양성솔위55.56%,LKM 양성솔위7.41%,AMA-M2양성솔위48.15%,SLA/LP 양성솔위7.41%,LC-1양성솔위3.70%。기타간병환자조 ANA 양성솔위26.26%,SMA 양성솔위4.55%,AMA 양성솔위11.11%,LKM 양성솔위0.51%,AMA-M2양성솔위5.05%,SLA/LP양성솔위2.53%,LC-1양성솔위1.52%。ALD환자조자신항체양성솔여기타간병환자조상비교,ANA、AMA、LKM、AMA-M2차이균유통계학의의(P균<0.05)。결론 ALD환자자신항체검출솔교고,위림상의생감별병독성간염、ALD급기타간병제공가고의거。
Objective To investigate the clinical value of autoantibodies detection in autoimmune liv-er disease(ALD) including autoimmune hepatitis(AIH), primary biliary cirrhosis(PBC) and primary scleros-ing cholangitis (PSC). Methods From January 2013 to February 2014, 225 patients from department of gas-troenterology, department of hepatobiliary surgery and transplant surgery were collected. Antinuclear antibody (ANA), antismooth muscle antibody(SMA) and anti-mitochondrial antibody(AMA) were detected by indirect immunofluorescence method. Liver kidney microsomal antibody(LKM), liver cytosol-1(LC-1), soluble anti-gen/liver pancreatic(SLA/LP) and AMA-M2 were tested by Europe and Mongolia blotting detection. The clin-ical datas were consulted and the detected results were analyzed statistically. Results The positive rates of ANA, SMA, AMA, LKM, AMA-M2, SLA/LP and LC-1 in patients with ALD were 77.78%, 7.41%, 55.56%, 7.41%, 48.15%, 7.41%and 3.70%, respectively. The positive rates of ANA, SMA, AMA, LKM, AMA-M2, SLA/LP and LC-1 in patients with other liver diseases were 26.26%, 4.55%, 11.11%, 0.51%, 5.05%, 2.53%and 1.52%, respectively. There were statistical significance in the differences of positive rates of ANA, AMA, LKM, AMA-M2 between ALD and other liver diseases group (Pall<0.05). Conclusion Au-toantibodies of ALD have a higher detection rate , and they provide a reliable basis for clinicians to identify vi-ral hepatitis, ALD and other liver diseases.